Editorials

Johnson & Johnson's third-quarter 10-Q, filed 2026-10-21 for the quarter ended 2026-09-27, shows two very different stories. Revenue and gross profit held steady. Pre-tax income nearly disappeared, and GAAP net income fell to $210 million. The gap sits almost entirely in one line: other nonoperating income and expense, which came in at a negative $5.78 billion in Q3 against roughly negative $0.3 billion in each of the prior two quarters. This piece walks through what the filing data does and does not show.

Reported revenue was $24.06B in Q1, $25.31B in Q2 and $25.40B in Q3, for $74.77B over nine months. Cost of goods sold was nearly flat across the three quarters ($8.11B, $8.05B, $8.10B), so gross profit tracked revenue. Gross margin, derived from reported gross profit divided by revenue, was 66.3% in Q1, 68.2% in Q2 and 68.1% in Q3. Q3 gross margin was essentially unchanged from Q2, so the Q3 earnings problem did not come from product-level economics.

Below gross profit, the picture shifts. Research and development rose from $3.65B in Q2 to $4.65B in Q3, an increase of about $1.0B. Selling, general and administrative expense fell about $0.15B over the same period. Combined, R&D plus SG&A rose about $0.85B quarter over quarter. Gross profit less those two lines fell from roughly $7.17B in Q2 to roughly $6.37B in Q3.

The filing extract does not include a reported operating income line. What the tagged lines do show is that the pre-nonoperating operating base in Q3 was materially larger than $4B on the gross-profit-less-R&D-and-SG&A measure, and that other operating lines not in the extract account for the remainder of the reported pre-tax figure.

The other nonoperating line moved from negative $331 million in Q2 to negative $5.78 billion in Q3, a swing of about $5.45 billion. Against about $2.45 billion of diluted weighted shares in Q3, that line equals roughly $2.36 per diluted share pre-tax. Before this line, Q3 pre-tax income would have been about $5.81 billion (reported pre-tax of $34 million plus the $5.78 billion charge), compared with about $7.08 billion in Q2 on the same basis.

Tax made the effect worse in optical terms. Q3 recorded a tax benefit of $176 million on $34 million of pre-tax income, which produced net income of $210 million. The filing extract does not break out the tax treatment of the charge, so the effective tax rate for Q3 is not meaningful as a run-rate measure. Q1 and Q2 effective rates were about 12.6% and 18.0%, respectively, on the same arithmetic.

Nine-month reported net income is $10.98B, made up of $5.24B in Q1, $5.53B in Q2 and $0.21B in Q3. Q1 and Q2 were close to each other, and both carried only modest nonoperating drag of about $0.3B per quarter. Q3 is the outlier. Excluding the Q3 nonoperating line, pre-tax income moved from about $7.08B in Q2 to about $5.81B in Q3, a decline of roughly 18%. That step-down is consistent with the roughly $0.85B increase in R&D and SG&A, though not every dollar of the decline is explained by the extract.

In other words, the Q3 GAAP collapse is two effects stacked together: a real but moderate operating step-down, driven mainly by higher R&D, and a very large nonoperating charge that the extract cannot yet characterize. Only the second is large enough to explain the headline EPS of $0.09.

Stockholders' equity fell from $84.97B at Q2 to $81.53B at Q3, and retained earnings fell from $171.67B to $168.36B. Cash and equivalents declared at quarter-end were $16.91B, down from $20.42B at Q2. Long-term debt was $35.80B and short-term borrowings were $8.85B at quarter-end. Q3 also shows roughly $17.1B of business acquisition payments in the cash flow extract. Note that the cash flow extract appears to mix year-to-date and quarterly presentations across periods, and the Q1 acquisition figure carries a positive sign where a payment would normally be negative. Cash flow figures in this piece are therefore not used for conclusions until the source filing is checked.

The key-metrics feed reports a trailing P/E of about 38.9 and an earnings yield of about 2.6%. Those multiples are computed on trailing GAAP earnings that now include the Q3 charge, so they are depressed in their earnings denominator and should not be read as a clean measure of the business. Reported revenue growth was about 6.0% year over year, and the three-year revenue CAGR was about 5.6%. The reader should decide how much weight to give a single nonoperating quarter when judging the business's earning power.

A Buffett-style reading of this quarter turns on three questions the filing data cannot yet answer:

1. Is the Q3 nonoperating charge recurring? Q1 and Q2 show small negative balances in this line. FY2025 shows that the same line has been very large in both directions. If the Q3 item is a one-time or reserve-related charge, Q3 GAAP earnings understate the core run-rate. If it is a recurring feature of the business, the GAAP-earnings line is more volatile than the operating line suggests.
2. Is the R&D step-up the new base? R&D rose about $1.0B quarter over quarter. Whether this reflects a sustained increase in investment or a timing item is an operating question, and it bears directly on the operating base.
3. How will the tax benefit reverse? The Q3 benefit of $176 million on near-zero pre-tax income will not repeat automatically. Its treatment in the 10-Q tax note should be checked.

The defensible summary from the reported data is this: gross margin held near 68% in Q2 and Q3, revenue grew modestly, and the Q3 GAAP earnings decline is driven by a single large nonoperating line of $5.78B whose nature is not identified in the data available to Moatkeep. The earnings-quality question is therefore open, and the 10-Q's other income and expense note is the next document to read.